The later finding, of association between chemotherapy administration and increased PD-L1 expression, presumes that sequential therapeutic protocols, based on initial administration of chemotherapeutic factors, preceded by immune checkpoint inhibitors (ICIs), could considerably propagate immunotherapy tumor-suppressing capacity [49]. This evidence concerns the gene CD274 and neoplasm.